Stockscreener 앱 받기
313.45
0.56%
1.76
시간 외 거래:
313.45
전일 마감가:
$311.69
열려 있는:
$311.98
하루 거래량:
479.94K
Relative Volume:
0.78
시가총액:
$22.06B
수익:
$2.36B
순이익/손실:
$236.10M
주가수익비율:
95.27
EPS:
3.29
순현금흐름:
$382.50M
1주 성능:
+1.53%
1개월 성능:
-10.04%
6개월 성능:
+22.33%
1년 성능:
+37.60%
1일 변동 폭
$310.02
$315.44
1주일 범위
$288.02
$316.59
52주 변동 폭
$225.37
$353.50
인슐렛 코퍼레이션 Stock (PODD) Company Profile
명칭
Insulet Corporation
전화
978-600-7000
주소
100 NAGOG PARK, ACTON, MA
PODD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
313.45 | 21.94B | 2.36B | 236.10M | 382.50M | 3.29 |
|
ABT
Abbott Laboratories
|
133.02 | 232.77B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
95.90 | 143.29B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
369.24 | 140.03B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
98.33 | 126.25B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
76.72 | 44.95B | 5.69B | 1.41B | 577.90M | 6.9828 |
인슐렛 코퍼레이션 Stock (PODD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-08 | 재개 | Oppenheimer | Outperform |
| 2025-06-16 | 개시 | Truist | Buy |
| 2025-05-30 | 개시 | Goldman | Buy |
| 2025-05-13 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | 개시 | RBC Capital Mkts | Outperform |
| 2024-11-06 | 개시 | Bernstein | Outperform |
| 2024-05-30 | 개시 | Redburn Atlantic | Buy |
| 2024-05-07 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-21 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-08-21 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-01-26 | 개시 | Wolfe Research | Peer Perform |
| 2022-11-04 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | 개시 | Barclays | Equal Weight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-02-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-02-02 | 업그레이드 | UBS | Neutral → Buy |
| 2022-01-31 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-07-21 | 재개 | Cowen | Outperform |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-01 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-07-28 | 개시 | Wells Fargo | Overweight |
| 2020-04-24 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | 개시 | BofA/Merrill | Neutral |
| 2020-03-31 | 다운그레이드 | Berenberg | Buy → Hold |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-12-10 | 개시 | CFRA | Sell |
| 2019-10-23 | 개시 | Stifel | Hold |
| 2019-10-18 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2019-10-04 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-10-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-08-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-06-10 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2018-04-20 | 개시 | Berenberg | Buy |
| 2018-02-22 | 재확인 | Barclays | Overweight |
| 2018-01-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | 개시 | Barclays | Overweight |
모두보기
인슐렛 코퍼레이션 주식(PODD)의 최신 뉴스
Real time scanner hits for Insulet Corporation explainedRisk Management & Technical Pattern Alert System - newser.com
Why analysts remain bullish on Insulet Corporation stockGold Moves & Long-Term Growth Portfolio Plans - newser.com
Insulet (PODD): A Fresh Look at Valuation Following Raised Guidance and Strong Q2 Growth - simplywall.st
How sentiment analysis helps forecast Insulet CorporationMarket Weekly Review & Fast Moving Market Watchlists - newser.com
What Analyst Watch Lists Suggest About Simplex Infrastructures Limiteds MomentumEarnings Revision Updates & Minimal Investment Trading Tips - earlytimes.in
How Investors Are Reacting To Insulet (PODD) Raising Guidance After Surging Q2 Revenue and New Product Launch - simplywall.st
Rothschild & Co Redburn Adjusts Price Target on Insulet to $370 From $350, Maintains Buy Rating - MarketScreener
Can Omnipod Mango’s Bold Design Shift Signal a New Strategy for Insulet (PODD)? - simplywall.st
Is Insulet Corporation (GOV) stock a buy for dividend portfoliosJuly 2025 Breakouts & Reliable Price Breakout Alerts - newser.com
Insulet Corporation stock retracement – recovery analysisEarnings Risk Summary & High Accuracy Trade Signal Alerts - newser.com
Will Insulet Corporation (GOV) stock deliver stable dividendsForecast Cut & AI Based Buy and Sell Signals - newser.com
What RSI levels show for Insulet Corporation (GOV) stockMarket Activity Report & Real-Time Chart Breakout Alerts - newser.com
Canaccord Genuity Raises Price Target on Insulet Corporation (PODD) to $399, Maintains Buy Rating - Yahoo Finance
Healthcare Stocks With Consistent 10%+ Revenue Growth - TIKR.com
Insulet Corporation (PODD) Q2 Revenue Surges 32.9% to $649M, Raises Full-Year Guidance - Yahoo Finance
Oversold Conditions For Insulet (PODD) - Nasdaq
Chicago Capital LLC Has $55.92 Million Stock Holdings in Insulet Corporation $PODD - MarketBeat
Canaccord Genuity raises Insulet stock price target to $399 on T2D advantage - Investing.com Nigeria
Why Insulet (PODD) is a Top Growth Stock for the Long-Term - Yahoo Finance
Insulet (PODD) Sees Target Price Raised by Canaccord Genuity | P - GuruFocus
A Glimpse Into The Expert Outlook On Insulet Through 6 Analysts - Benzinga
Canaccord Genuity Maintains Insulet (PODD) Buy Recommendation - Nasdaq
Insulet Corporation (PODD) PT Raised to $399 at Canaccord Genuity - StreetInsider
The Mango Move: How Insulet's Colourful Strategy Is Ripe For AttentionTrademarkUnited Kingdom - Mondaq
Insulet Corporation (PODD) Stock Analysis: Healthcare Innovator with a 13.89% Upside Potential - DirectorsTalk Interviews
Is Insulet Corporation GOV a good long term investmentREITs Market Trends & Discover Your Financial Freedom Formula - earlytimes.in
Insulet Appoints New CFO Amid Revenue Growth - MSN
Insulet Corporation GOV Stock Analysis and ForecastEnergy Sector Updates & Affordable Investment Tips - earlytimes.in
Patton Fund Management Inc. Makes New Investment in Insulet Corporation $PODD - MarketBeat
Insulet Corporation $PODD Shares Acquired by Congress Asset Management Co. - MarketBeat
Western Financial Corp CA Makes New $1.06 Million Investment in Insulet Corporation $PODD - MarketBeat
Public Employees Retirement System of Ohio Trims Position in Insulet Corporation $PODD - MarketBeat
What drives Insulet Corporation stock priceIndustrial Stocks Review & Smart Beta Strategies That Actually Work - Early Times
Will Insulet Corporation price bounce be sustainable2025 Earnings Surprises & Daily Stock Trend Reports - newser.com
Insulet Stock Surges 37.4% in 12 months: What's Driving the Rally? - sharewise.com
Novem Group Acquires New Holdings in Insulet Corporation $PODD - MarketBeat
Align Technology, ResMed, Insulet, Envista, and Dentsply Sirona Shares Plummet, What You Need To Know - Yahoo Finance
Beacon Investment Advisory Services Inc. Sells 33,261 Shares of Insulet Corporation $PODD - MarketBeat
Is Insulet Stock Outperforming the S&P 500? - Yahoo Finance
Is Insulet Stock Outperforming The S&P 500? - Barchart.com
인슐렛 코퍼레이션 (PODD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.38%
0.50%
자본화:
|
볼륨(24시간):